KEYNOTE-016 was a phase 2 study that evaluated the clinical activity of pembrolizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, in patients with progressive metastatic carcinoma with or without dMMR [7,8]. The gene discussed is PDCD1; the disease is metastatic carcinoma.